Alexander Olegovitch Kibitov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexander Olegovitch Kibitov has a total of 368 co-authors. Here are the top co-authors by number of shared publications:
- Grigory V. Rukavishnikov
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
25 shared publications - Galina Elevna Mazo
Department of Social neuropsychiatry V. M. Bekhterev National Medical Research Center for Psychiatry and Neurology Saint-Petersburg Russia
23 shared publications - Evgeny Dmitrievich Kasyanov
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
22 shared publications N.A. Chuprova
V. Serbsky National Medical Research Centre for Psychiatry and Narcology
13 shared publications- Evgeny Krupitsky
Saint Petersburg First Pavlov State Medical University, Saint Petersburg 197022, Russia; V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg 192019, Russia
11 shared publications A.E. Nikolishin
V. Serbsky National Medical Research Centre for Psychiatry and Narcology
10 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by ECO-Vector LLC (Publications) in Psychopharmacology and Addiction Biology
Real-world clinical practice for planning clinical trials of psychopharmacotherapy efficacy
This article examines the value of real-world clinical practice (RCP) research in expanding the evidence-based medicine paradigm in psychiatry.Although randomized clinical trials (RCTs) are considered the "gold standard", they have limitations and are not always feasible in certain clinical scenarios, including pregnancy, pediatric and geriatric populations, comorbidity, and treatment-resistant conditions. RCP research — which incorporates registry data and observational studies — enables the identification of prescribing patterns in psychopharmacotherapy, the assessment of long-term efficacy and safety, and provides a foundation for more targeted and pragmatic RCT design. The value of RCP research is illustrated with concrete examples. The article also discusses the potential of the Federal Register of Patients with Mental Disorders (FRPMD), currently being developed in Russia, as a data source for future studies.
- 7 November 2026
- Published by ECO-Vector LLC (Publications) in Psychopharmacology and Addiction Biology
Open AccessReal-world clinical practice for planning clinical trials of psychopharmacotherapy efficacy
This article examines the value of real-world clinical practice (RCP) research in expanding the evidence-based medicine paradigm in psychiatry.Although randomized clinical trials (RCTs) are considered the "gold standard", they have limitations and are not always feasible in certain clinical scenarios, including pregnancy, pediatric and geriatric populations, comorbidity, and treatment-resistant conditions. RCP research — which incorporates registry data and observational studies — enables the identification of prescribing patterns in psychopharmacotherapy, the assessment of long-term efficacy and safety, and provides a foundation for more targeted and pragmatic RCT design. The value of RCP research is illustrated with concrete examples. The article also discusses the potential of the Federal Register of Patients with Mental Disorders (FRPMD), currently being developed in Russia, as a data source for future studies.
- Open Access
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Pharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Open AccessPharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- Open Access
- 8 September 2026
- Published by ECO-Vector LLC (Publications) in Psychopharmacology and Addiction Biology
- Vol. 17 (2) , 71-80
Modern psychopharmacology: systemic integration of molecular modeling, omics technologies, translational experimental models, and evidence-based clinical studies
This article summarizes the materials of three symposia on psychopharmacology held within the framework of the XIII All-Russian Conference with International Participation “Current Issues in Preclinical and Clinical Research of Medicinal Products and Clinical Trials of Medical Devices” (St. Petersburg, April 23–24, 2026). The development of modern psychopharmacology requires the implementation of personalized approaches, the application of molecular modeling and computational biology methods, and the integration of pharmacogenetic, pharmacoepigenomic, and multi-omics data into drug development and efficacy assessment processes. The priority areas for the development of modern psychopharmacology are: 1) implementation of integrated in silico pipelines at all stages of drug development; 2) active application of molecular modeling approaches for the creation of innovative drugs and targeted delivery systems; 3) development of standardized translational models ensuring high reproducibility and predictive value of experimental results at the preclinical research stage; and 4) integration of pharmacogenomic, pharmacoepigenomic, and multi-omics methods and assessments into the design of clinical studies. For the development of modern psychopharmacology, it is primarily necessary to: 1) improve the regulatory and methodological framework governing the use of modern digital and computational technologies, including artificial intelligence, in the development of medicinal products and medical devices; 2) resolve issues of standardization and validation of in silico modeling data, as well as introduce pharmacogenetic approaches into the clinical practice of psychiatry and addiction medicine; 3) develop a system of training specialists at the intersection of medicine, biology, bioinformatics, cheminformatics, and information technologies; and 4) create multidisciplinary research consortia. Thus, the further development of psychopharmacology is impossible without close systemic integration of fundamental research using omics technologies, computational technologies, translational models, and high-quality clinical studies. The implementation of such integrative projects will contribute to improving the efficiency of developing innovative drugs and to the advancement of personalized psychiatry and addiction medicine.
- 8 September 2026
- Published by ECO-Vector LLC (Publications) in Psychopharmacology and Addiction Biology
- Vol. 17 (2) , 71-80
Open AccessModern psychopharmacology: systemic integration of molecular modeling, omics technologies, translational experimental models, and evidence-based clinical studies
This article summarizes the materials of three symposia on psychopharmacology held within the framework of the XIII All-Russian Conference with International Participation “Current Issues in Preclinical and Clinical Research of Medicinal Products and Clinical Trials of Medical Devices” (St. Petersburg, April 23–24, 2026). The development of modern psychopharmacology requires the implementation of personalized approaches, the application of molecular modeling and computational biology methods, and the integration of pharmacogenetic, pharmacoepigenomic, and multi-omics data into drug development and efficacy assessment processes. The priority areas for the development of modern psychopharmacology are: 1) implementation of integrated in silico pipelines at all stages of drug development; 2) active application of molecular modeling approaches for the creation of innovative drugs and targeted delivery systems; 3) development of standardized translational models ensuring high reproducibility and predictive value of experimental results at the preclinical research stage; and 4) integration of pharmacogenomic, pharmacoepigenomic, and multi-omics methods and assessments into the design of clinical studies. For the development of modern psychopharmacology, it is primarily necessary to: 1) improve the regulatory and methodological framework governing the use of modern digital and computational technologies, including artificial intelligence, in the development of medicinal products and medical devices; 2) resolve issues of standardization and validation of in silico modeling data, as well as introduce pharmacogenetic approaches into the clinical practice of psychiatry and addiction medicine; 3) develop a system of training specialists at the intersection of medicine, biology, bioinformatics, cheminformatics, and information technologies; and 4) create multidisciplinary research consortia. Thus, the further development of psychopharmacology is impossible without close systemic integration of fundamental research using omics technologies, computational technologies, translational models, and high-quality clinical studies. The implementation of such integrative projects will contribute to improving the efficiency of developing innovative drugs and to the advancement of personalized psychiatry and addiction medicine.
- 1 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Healthy young adults with a family history of alcohol dependence: Suicidal ideation, anxiety, and «novelty-seeking»
Objective. To investigate the associations between a family history of alcohol dependence (AD) and the mental health disorders and personal traits of healthy young adults. Material and methods. The study included 95 healthy subjects, with an average age of 20.68±2.45 years, of whom 80.0% were women. The study utilized a self-administered questionnaire that included a comprehensive study map and psychometric scales. Participants were categorized into two groups: individuals without a relevant family history of AD and those with a relevant family history of AD. The latter group was further divided into two subgroups based on the family history: individuals with a moderate family burden of AD (1 relative with AD), designated, and those with a high family burden of AD (2 or more relatives with AD), designated. Comparative analyses were conducted across all study variables. Results. Several significant associations were identified between a family history of AD, particularly with a high burden, and various psychological and somatic indicators. Notably, there was a correlation between a family history of AD and affective symptoms, specifically the presence and severity of anxiety symptoms (p=0.003) as well as the suicidal ideation (p=0.015), but not attempted suicides. Additionally, a relationship was established with personality traits, particularly the propensity for «novelty-seeking» behaviors (p=0.001), and a potential link to eating disorders. Furthermore, a family history of AD was correlated with general somatic health, including associations with familial obesity (p=0.0002) and overall indicators of physical health. Conclusions. Future investigations with larger samples are essential to elucidate further the specific impacts of both the presence and grade of a family history of alcohol dependence, serving as a potential marker for the risk of developing mental health and substance use disorders at a preclinical stage.
- 1 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Healthy young adults with a family history of alcohol dependence: Suicidal ideation, anxiety, and «novelty-seeking»
Objective. To investigate the associations between a family history of alcohol dependence (AD) and the mental health disorders and personal traits of healthy young adults. Material and methods. The study included 95 healthy subjects, with an average age of 20.68±2.45 years, of whom 80.0% were women. The study utilized a self-administered questionnaire that included a comprehensive study map and psychometric scales. Participants were categorized into two groups: individuals without a relevant family history of AD and those with a relevant family history of AD. The latter group was further divided into two subgroups based on the family history: individuals with a moderate family burden of AD (1 relative with AD), designated, and those with a high family burden of AD (2 or more relatives with AD), designated. Comparative analyses were conducted across all study variables. Results. Several significant associations were identified between a family history of AD, particularly with a high burden, and various psychological and somatic indicators. Notably, there was a correlation between a family history of AD and affective symptoms, specifically the presence and severity of anxiety symptoms (p=0.003) as well as the suicidal ideation (p=0.015), but not attempted suicides. Additionally, a relationship was established with personality traits, particularly the propensity for «novelty-seeking» behaviors (p=0.001), and a potential link to eating disorders. Furthermore, a family history of AD was correlated with general somatic health, including associations with familial obesity (p=0.0002) and overall indicators of physical health. Conclusions. Future investigations with larger samples are essential to elucidate further the specific impacts of both the presence and grade of a family history of alcohol dependence, serving as a potential marker for the risk of developing mental health and substance use disorders at a preclinical stage.
- Open Access
- 28 May 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (2) , 17-27
Suicide Prevention Programs for Patients with Schizophrenia and Schizophrenia Spectrum Disorders: A Review of Russian Studies
Rationale . Suicide is a significant cause of death in patients with schizophrenia and schizophrenia spectrum disorders (SSDs). Therefore, developing effective methods for suicide prevention is a pressing scientific and practical challenge in psychiatric practice. Globally, various intervention programs aimed at preventing suicidal behavior in patients with schizophrenia and SSDs have been developed and are in use. The objective of this study was to search, systematize, and generalize data from Russian-language scientific sources regarding specific interventions (programs, models, strategies, and systems) aimed at preventing suicidal behavior in patients with schizophrenia and SSDs. Material and Methods . A search and analysis of Russian-language articles were conducted in the academic electronic libraries (database libraries) eLIBRARY. ru and CyberLeninka using various combinations of the following keywords: «program», «strategy», «model», «system», «prevention», «suicidal behavior», «suicide» and «schizophrenia». Results . The search did not identify any specialized suicidal behavior prevention programs developed for patients with schizophrenia and SSDs. Conclusion . According to the analysis of Russian scientific literature, there are currently no suicide prevention programs available in our country for patients with schizophrenia and SSDs. The development, approbation, and integration of such programs are essential for improving the quality of psychiatric care, enhancing treatment outcomes, and reducing mortality. This will require a comprehensive approach, including staff training, the development of specific protocols, and the creation of accessible support resources for patients. There is a clear need to develop such programs at both the regional and national levels. The existing practical experience in organizing suicide prevention measures within the general population and among patients with other mental disorders at the regional and individual institutional levels must be adapted and utilized for targeted suicide prevention programs for patients with schizophrenia and SSDs.
- 28 May 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (2) , 17-27
Open AccessSuicide Prevention Programs for Patients with Schizophrenia and Schizophrenia Spectrum Disorders: A Review of Russian Studies
Rationale . Suicide is a significant cause of death in patients with schizophrenia and schizophrenia spectrum disorders (SSDs). Therefore, developing effective methods for suicide prevention is a pressing scientific and practical challenge in psychiatric practice. Globally, various intervention programs aimed at preventing suicidal behavior in patients with schizophrenia and SSDs have been developed and are in use. The objective of this study was to search, systematize, and generalize data from Russian-language scientific sources regarding specific interventions (programs, models, strategies, and systems) aimed at preventing suicidal behavior in patients with schizophrenia and SSDs. Material and Methods . A search and analysis of Russian-language articles were conducted in the academic electronic libraries (database libraries) eLIBRARY. ru and CyberLeninka using various combinations of the following keywords: «program», «strategy», «model», «system», «prevention», «suicidal behavior», «suicide» and «schizophrenia». Results . The search did not identify any specialized suicidal behavior prevention programs developed for patients with schizophrenia and SSDs. Conclusion . According to the analysis of Russian scientific literature, there are currently no suicide prevention programs available in our country for patients with schizophrenia and SSDs. The development, approbation, and integration of such programs are essential for improving the quality of psychiatric care, enhancing treatment outcomes, and reducing mortality. This will require a comprehensive approach, including staff training, the development of specific protocols, and the creation of accessible support resources for patients. There is a clear need to develop such programs at both the regional and national levels. The existing practical experience in organizing suicide prevention measures within the general population and among patients with other mental disorders at the regional and individual institutional levels must be adapted and utilized for targeted suicide prevention programs for patients with schizophrenia and SSDs.
- 13 February 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (6)
Thyroid Diseases are Associated with the Severity of Eating Disorders in Patients with Depression: Exploratory Analysis
Background: the presence of symptoms of Eating disorder (ED) in the structure of depression can potentially increase the risk of developing cardiovascular, endocrine and neurological diseases, which must be taken into account in the diagnosis and approaches to the treatment of these disorders. The aim of study: conducting an exploratory analysis of the relationship between depression and the severity of ED depending on concomitant somatic diseases and mental disorders. Patients and Methods: a cross-sectional study included 338 patients (63.9% females; the average age was 30.8 years). Their mental state was diagnosed as depressive episode (F32) or recurrent depressive disorder (F33) on the ICD-10. The study card recorded data on the presence of somatic diseases. All participants underwent a psychometric examination using the EAT-26 test. Results: patients with depression and concomitant thyroid diseases had significantly more pronounced ED according to EAT-26. In addition, patients with a family history of thyroid disease tended to have not significantly higher scores on the EAT-26 scale. At the same time, the presence of thyroid disease in patients with depression was not associated with concomitant anorexia nervosa and bulimia nervosa. Conclusions : patients with depression and concomitant thyroid disease have a higher severity of thyroid disease (TD), but not the increased frequency of clinically significant eating disorders. This result can be explained by the broader clinical characteristics of TD, which is quantitatively assessed by EAT-26 and which may overlap the symptoms of depression. The relationship between depression, TD and ED can be explained by the influence of thyroid hormones on the regulation of metabolism and neurovegetative functions, including through the leptin system. Further studies are required to confirm this hypothesis.
- 13 February 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (6)
Thyroid Diseases are Associated with the Severity of Eating Disorders in Patients with Depression: Exploratory Analysis
Background: the presence of symptoms of Eating disorder (ED) in the structure of depression can potentially increase the risk of developing cardiovascular, endocrine and neurological diseases, which must be taken into account in the diagnosis and approaches to the treatment of these disorders. The aim of study: conducting an exploratory analysis of the relationship between depression and the severity of ED depending on concomitant somatic diseases and mental disorders. Patients and Methods: a cross-sectional study included 338 patients (63.9% females; the average age was 30.8 years). Their mental state was diagnosed as depressive episode (F32) or recurrent depressive disorder (F33) on the ICD-10. The study card recorded data on the presence of somatic diseases. All participants underwent a psychometric examination using the EAT-26 test. Results: patients with depression and concomitant thyroid diseases had significantly more pronounced ED according to EAT-26. In addition, patients with a family history of thyroid disease tended to have not significantly higher scores on the EAT-26 scale. At the same time, the presence of thyroid disease in patients with depression was not associated with concomitant anorexia nervosa and bulimia nervosa. Conclusions : patients with depression and concomitant thyroid disease have a higher severity of thyroid disease (TD), but not the increased frequency of clinically significant eating disorders. This result can be explained by the broader clinical characteristics of TD, which is quantitatively assessed by EAT-26 and which may overlap the symptoms of depression. The relationship between depression, TD and ED can be explained by the influence of thyroid hormones on the regulation of metabolism and neurovegetative functions, including through the leptin system. Further studies are required to confirm this hypothesis.
- Open Access
- 22 December 2025
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (5) , 28-41
Association of Family History and Adverse Childhood Experiences with Nonsuicidal and Suicidal Self-Injury in Patients with Affective Disorders
Background: affective disorders are among the most common mental disorders associated with a high risk of suicide and non-suicidal self-injurious behavior (NSSI). However, little is known about the complex impact of family history (FH) and adverse childhood experiences (ACE) on this risk. The Aim was to study the association of ACE and FH with NSSI and suicide attempts in patients with affective disorders. Patients and Methods: the sample consisted of 199 patients (74.9% ( n = 149) women, median (Q1–Q3) age 27 (22–36) years) with bipolar affective disorder (73.9% ( n = 147) and depression (recurrent depressive disorder, depressive episode). More than half of included patients reported a history of NSSI (51.3%; n = 102), more than a third had a history of suicide attempts (34.2%; n = 68). Sociodemographic characteristics and information on FH were collected during a clinical interview. ACE was assessed using the Adverse Childhood Experiences International Questionnaire (ACE-IQ). Between group comparisons and logistic regression were used to comprehensively assess the impact of FH, ACE, gender, age, and diagnosis on the lifetime NSSI and suicide attempts prevalence. Results: between-group comparisons demonstrated an association of FH of suicide attempts and certain kinds of ACE with NSSI and suicide attempts. Logistic regression revealed significant associations of FH of suicide (OR = 3.741, p = 0.047) and emotional neglect (OR = 2.951, p = 0.027) with suicide attempts, as well as significant associations of sexual abuse (OR = 3.788, p = 0.029), parental deprivation (OR = 3.191, p = 0.024), age (for each year, OR = 0.823, p < 0.001), and the FH of mental disorders (OR = 0.281, p = 0.017) with NSSI. Conclusions: the results of study demonstrate the importance of joint assessment of genetic and environmental factors to create complex predictive models of suicide attempt and NSSI in patients with affective disorders.
- 22 December 2025
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 23 (5) , 28-41
Open AccessAssociation of Family History and Adverse Childhood Experiences with Nonsuicidal and Suicidal Self-Injury in Patients with Affective Disorders
Background: affective disorders are among the most common mental disorders associated with a high risk of suicide and non-suicidal self-injurious behavior (NSSI). However, little is known about the complex impact of family history (FH) and adverse childhood experiences (ACE) on this risk. The Aim was to study the association of ACE and FH with NSSI and suicide attempts in patients with affective disorders. Patients and Methods: the sample consisted of 199 patients (74.9% ( n = 149) women, median (Q1–Q3) age 27 (22–36) years) with bipolar affective disorder (73.9% ( n = 147) and depression (recurrent depressive disorder, depressive episode). More than half of included patients reported a history of NSSI (51.3%; n = 102), more than a third had a history of suicide attempts (34.2%; n = 68). Sociodemographic characteristics and information on FH were collected during a clinical interview. ACE was assessed using the Adverse Childhood Experiences International Questionnaire (ACE-IQ). Between group comparisons and logistic regression were used to comprehensively assess the impact of FH, ACE, gender, age, and diagnosis on the lifetime NSSI and suicide attempts prevalence. Results: between-group comparisons demonstrated an association of FH of suicide attempts and certain kinds of ACE with NSSI and suicide attempts. Logistic regression revealed significant associations of FH of suicide (OR = 3.741, p = 0.047) and emotional neglect (OR = 2.951, p = 0.027) with suicide attempts, as well as significant associations of sexual abuse (OR = 3.788, p = 0.029), parental deprivation (OR = 3.191, p = 0.024), age (for each year, OR = 0.823, p < 0.001), and the FH of mental disorders (OR = 0.281, p = 0.017) with NSSI. Conclusions: the results of study demonstrate the importance of joint assessment of genetic and environmental factors to create complex predictive models of suicide attempt and NSSI in patients with affective disorders.
- Open Access
- 12 December 2025
- Published by ECO-Vector LLC (Publications) in Consortium Psychiatricum
- Vol. 6 (4) , 24-34
Moderating effect of metacognition on the relationship between perfectionism, body image disturbance, and body mass index in anorexia nervosa: a cross-sectional study
BACKGROUND: Despite theoretical concepts about the key role of perfectionism in the formation of the symptoms of anorexia nervosa (AN), the aspects of the mutual influence between body mass index (BMI), perfectionism, and body image in patients with AN remain insufficiently studied or contradictory. Studying integrative cognitive processes, such as metacognition, may reveal new mechanisms of perfectionism’s influence on the clinical manifestations of AN. AIM: The assessment of the moderating effect of metacognition on perfectionism associated with BMI and body image in patients with AN. METHODS: A cross-sectional study was conducted involving patients with AN who were undergoing inpatient treatment. Perception of one’s own body was assessed using the Body Image Questionnaire. Perfectionism was assessed using the Multidimensional Perfectionism Scale. The level of metacognition of patients was assessed using the Metacognition Assessment Scale-Abbreviated, which evaluates Self-reflectivity, Understanding the other’s mind, Decentration, and Mastery (the ability to develop adaptive strategies for coping and behaviour regulation). BMI was also recorded. RESULTS: A total of 130 patients were examined. At a Mastery score of ≥4 higher perfectionism scores were associated with an increase in BMI, and at a Mastery level of ≤1 a higher level of perfectionism was associated with decreasing of BMI. Even with minimal Self-reflectivity scores (≥2), the negative effect of perfectionism on body image was evident. Body image disturbance was positively correlated with perfectionism. No correlations were found between BMI and perfectionism and between BMI and body image disturbance. CONCLUSION: The effect of perfectionism on body image disturbance and BMI in patients with AN depends on the magnitude of Self-reflectivity and Mastery. The obtained data indicate the necessity of incorporating psychotherapy aimed at the development of metacognition in patients with AN.
- 12 December 2025
- Published by ECO-Vector LLC (Publications) in Consortium Psychiatricum
- Vol. 6 (4) , 24-34
Open AccessModerating effect of metacognition on the relationship between perfectionism, body image disturbance, and body mass index in anorexia nervosa: a cross-sectional study
BACKGROUND: Despite theoretical concepts about the key role of perfectionism in the formation of the symptoms of anorexia nervosa (AN), the aspects of the mutual influence between body mass index (BMI), perfectionism, and body image in patients with AN remain insufficiently studied or contradictory. Studying integrative cognitive processes, such as metacognition, may reveal new mechanisms of perfectionism’s influence on the clinical manifestations of AN. AIM: The assessment of the moderating effect of metacognition on perfectionism associated with BMI and body image in patients with AN. METHODS: A cross-sectional study was conducted involving patients with AN who were undergoing inpatient treatment. Perception of one’s own body was assessed using the Body Image Questionnaire. Perfectionism was assessed using the Multidimensional Perfectionism Scale. The level of metacognition of patients was assessed using the Metacognition Assessment Scale-Abbreviated, which evaluates Self-reflectivity, Understanding the other’s mind, Decentration, and Mastery (the ability to develop adaptive strategies for coping and behaviour regulation). BMI was also recorded. RESULTS: A total of 130 patients were examined. At a Mastery score of ≥4 higher perfectionism scores were associated with an increase in BMI, and at a Mastery level of ≤1 a higher level of perfectionism was associated with decreasing of BMI. Even with minimal Self-reflectivity scores (≥2), the negative effect of perfectionism on body image was evident. Body image disturbance was positively correlated with perfectionism. No correlations were found between BMI and perfectionism and between BMI and body image disturbance. CONCLUSION: The effect of perfectionism on body image disturbance and BMI in patients with AN depends on the magnitude of Self-reflectivity and Mastery. The obtained data indicate the necessity of incorporating psychotherapy aimed at the development of metacognition in patients with AN.
- 29 November 2025
- Published by LLC M-Center in Суицидология
- Vol. 16 (03(60))
Combined nonsuicidial and suicidal self-injurious behavior: transnosological role of family history and adverse childhood experiences
- 29 November 2025
- Published by LLC M-Center in Суицидология
- Vol. 16 (03(60))
Combined nonsuicidial and suicidal self-injurious behavior: transnosological role of family history and adverse childhood experiences